Xenon gas preservation of refrigerated platelets

Active Grant Awarded

Award ID
R43HL184078
Recipient
Awarding agency
Obligated
$479,185

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date 21% complete
Place of performance
Framingham, MA 01702, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute awarded General Biophysics LLC $479,185 in obligated funds on September 9, 2026, under Grant R43HL184078 in Assistance Listing 93.837, Cardiovascular Diseases Research. The award funds clinical trial testing of a device that stores and ships refrigerated platelets in a pressurized xenon atmosphere. The proposal states that the technology would allow refrigerated platelet storage for 14 days while preserving platelet function, recovery, and survival after transfusion. It also states that conventional refrigerated platelets cannot support therapeutic transfusion, which accounts for 95% of the platelet market, because they do not circulate after transfusion. The proposal cites preliminary data indicating that xenon reduces viscosity of extracellular membranes. The period of performance runs from September 9, 2026 through August 31, 2027, with place of performance in Framingham, Massachusetts 01702. The recipient's UEI is MTDKKELM58W5.

Description

Abstract
Platelets are the primary coagulation blood component used for transfusion in the course of operations, trauma surgery, transplantations and post cancer therapy. The management and distribution of platelets incurs significant costs and shortages relative to other blood components. They require special donation, testing and delivery processes. Platelets suffer higher losses due to increased outdates. Platelets are stored for up to 5 days at room temperature 22-24°C. There are two main factors that determine the shelf-life. First is a loss of quality - the stored platelets demonstrate decreased thrombotic functions compared to even fresh whole blood. Second reason is bacterial contamination, when platelets stored at room temperature and bacteria can proliferate. Other blood components can be stored for significantly longer times due to the ability to survive refrigeration or freezing. When platelets are refrigerated, they do not circulate after transfusion. Refrigerated platelets can be used to resuscitate bleeding patients as an exemption when conventional platelets are not available, but they are inapplicable for therapeutic transfusions (95% of the platelet market) due to extremely short circulation in the bloodstream and inability to sustainably increase patient's platelet count. The goal of this proposal is to test in the clinical trial a device that would enable storage and shipment of platelets at a refrigerated temperature in the atmosphere of pressurized xenon (XE). The developed technology will eliminate negative effects of refrigeration on platelet circulation after transfusion. Our technology will allow refrigerated storage of platelets for 14 days while preserving platelets functionality with recovery and survival after transfusion. XE is currently used in human patients as an anesthetic and as an imaging agent. Our preliminary data indicate that XE reduces viscosity of extracellular membranes, inhibiting clustering of VON willebrand factor (VWF) receptors gpiba on the surface of platelets. This prevents recognition of cold stored platelets by the tissue macrophages and their removal from circulation via phagocytosis. Based on the extensive research we already validated feasibility of this technology and received FDA's approval for the clinical trial. In this phase I sbir proposal, we will perform first in human clinical trial to evaluate recovery and survival of transfused platelets stored in our incubator. The proposed platelet storage technology will add significant value to the processing and distribution of platelets by increasing availability, eliminating outdate losses, and improving safety.

Quick answers

Who received award R43HL184078?

R43HL184078 was awarded to General Biophysics LLC by National Heart Lung and Blood Institute (National Institutes of Health) on September 9, 2026.

How much is award R43HL184078 worth?

$479,185 has been obligated on R43HL184078.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award